Voloridge Investment Management LLC Has $3.17 Million Position in Takeda Pharmaceutical Co Ltd (NYSE:TAK)

Voloridge Investment Management LLC increased its holdings in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 747.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 184,173 shares of the company’s stock after purchasing an additional 162,428 shares during the period. Voloridge Investment Management LLC’s holdings in Takeda Pharmaceutical were worth $3,168,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Prestige Wealth Management Group LLC bought a new position in Takeda Pharmaceutical in the second quarter valued at approximately $25,000. Parallel Advisors LLC increased its holdings in Takeda Pharmaceutical by 276.3% during the 3rd quarter. Parallel Advisors LLC now owns 1,509 shares of the company’s stock worth $26,000 after purchasing an additional 1,108 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new position in Takeda Pharmaceutical during the 2nd quarter worth about $31,000. Coastal Investment Advisors Inc. raised its stake in shares of Takeda Pharmaceutical by 59.8% in the 2nd quarter. Coastal Investment Advisors Inc. now owns 1,718 shares of the company’s stock valued at $32,000 after purchasing an additional 643 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in shares of Takeda Pharmaceutical by 4,645.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,898 shares of the company’s stock valued at $34,000 after purchasing an additional 1,858 shares during the period. Institutional investors and hedge funds own 4.58% of the company’s stock.

Shares of TAK opened at $20.56 on Tuesday. The stock has a market capitalization of $63.28 billion, a price-to-earnings ratio of 40.31 and a beta of 0.76. Takeda Pharmaceutical Co Ltd has a 12 month low of $15.50 and a 12 month high of $21.61. The firm has a fifty day simple moving average of $19.09 and a 200 day simple moving average of $17.76. The company has a current ratio of 1.45, a quick ratio of 0.94 and a debt-to-equity ratio of 1.00.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.59 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a net margin of 3.66% and a return on equity of 12.52%. The firm had revenue of $7.56 billion for the quarter. As a group, research analysts predict that Takeda Pharmaceutical Co Ltd will post 1.99 earnings per share for the current fiscal year.

TAK has been the subject of several recent research reports. Daiwa Capital Markets cut Takeda Pharmaceutical from an “outperform” rating to a “neutral” rating in a research report on Thursday, August 15th. Jefferies Financial Group assumed coverage on Takeda Pharmaceutical in a research report on Tuesday, September 24th. They issued a “buy” rating on the stock. Cowen assumed coverage on Takeda Pharmaceutical in a research note on Friday, November 1st. They issued a “market perform” rating and a $19.50 target price on the stock. ValuEngine cut Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. Finally, Zacks Investment Research raised Takeda Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. Takeda Pharmaceutical currently has a consensus rating of “Hold” and a consensus target price of $19.25.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Featured Story: Cost of Capital Explained

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co Ltd (NYSE:TAK).

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.